Psoriasis Clinical Trial
Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis
Summary
The purpose of this study is to compare the efficacy and safety of deucravacitinib to placebo in participants with moderate-to-severe scalp psoriasis.
Eligibility Criteria
Inclusion Criteria:
Men and women diagnosed with stable plaque psoriasis with scalp involvement for 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the Investigator
Deemed by the Investigator to be a candidate for phototherapy or systemic therapy
Moderate-to-severe scalp psoriasis as defined by scalp-specific Physician's Global Assessment (ss-PGA) ≥ 3; ≥ 20% scalp surface area (SSA); Psoriasis Scalp Severity Index (PSSI) ≥ 12 at the Screening visit and Day 1
≥ 3% of Body Surface Area (BSA) involvement at the Screening visit and Day 1
Evidence of plaque psoriasis in a non-scalp area
Failed to respond to, or intolerant of ≥ 1 topical therapy for scalp psoriasis
Exclusion Criteria:
Target Disease Exceptions:
Has nonplaque psoriasis (ie, guttate, inverse, pustular, erythrodermic or drug-induced psoriasis) at Screening or Day 1 Other protocol-defined inclusion/exclusion criteria apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 29 Locations for this study
Hot Springs Arkansas, 71913, United States
Indianapolis Indiana, 46256, United States
Louisville Kentucky, 40217, United States
Rockville Maryland, 20850, United States
Beverly Massachusetts, 01915, United States
Bloomfield Hills Michigan, 48302, United States
Fridley Minnesota, 55432, United States
East Windsor New Jersey, 08520, United States
Kew Gardens New York, 11415, United States
Portland Oregon, 97223, United States
Pittsburgh Pennsylvania, 15213, United States
Houston Texas, 77004, United States
San Antonio Texas, 78229, United States
Norfolk Virginia, 23502, United States
Paris , 75010, France
Romans sur Isere Cedex , 26102, France
Rouen Cedex , 76031, France
Witten Deutschland, 58454, Germany
Frankfurt Hessen, 60590, Germany
Hamburg , 20246, Germany
Luebeck , 23538, Germany
Mahlow , 15831, Germany
Krakow , 30438, Poland
Lodz , 90-43, Poland
Rzeszow , 35-05, Poland
Wroclaw , 51-68, Poland
London Greater London, SE1 9, United Kingdom
Salford Greater Manchester, M6 8H, United Kingdom
Southampton Hampshire, SO16 , United Kingdom
How clear is this clinincal trial information?